---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-093930"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:16:38.568404+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio submits Phase 2 MINDFuL manuscript; highlights subgroup benefit and no ARIA

## Summary
- Phase 2 MINDFuL trial of XPro1595 missed primary endpoint overall but showed positive trends in ADi subgroup with high inflammatory burden.
- No amyloid-related imaging abnormalities (ARIA) observed, even in high-risk patients (APOE4 carriers, anticoagulants, microbleeds).
- Manuscript submitted to npj Dementia (Nature Portfolio); preprint available on medRxiv.
- Expects FDA feedback for end-of-Phase 2 discussions in Q1 2026.
- XPro1595 selectively neutralizes soluble TNF, targeting neuroinflammation in precision medicine approach.

## SEC filing metadata
- accession: 0001213900-25-093930
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/0001213900-25-093930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025093930/ea0258531-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-093930
- JSON: https://secwatch.observer/filing/0001213900-25-093930.json
- Plain text: https://secwatch.observer/filing/0001213900-25-093930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.